Backgrounds: Glycoprotein 2[GP2] and CUB zona pellucida-like domain 1[CUZD1] belong to protein families involved in gut innate immunity processes and have recently been identified as specific targets of anti-pancreatic autoantibodies [PAbs] in Crohn's disease [CD]. We aimed to determine the prognostic potential of novel target-specific PAbs regarding long-term disease course of an adult CD patient cohort. 
Introduction
Inflammatory bowel diseases [IBD] are chronic inflammatory disorders of the gastrointestinal tract. Both Crohn's disease [CD] and ulcerative colitis [UC] are heterogeneous in their presentation and disease course. Serological antibodies have been reported to assist in the diagnosis, differential diagnosis, and prediction of either disease course or response to therapy in IBD. 1 There is accumulating evidence from cross-sectional, longitudinal studies and meta-analyses that support the value of serological markers in identifying patients with complicated disease phenotype and increased risk of surgery in patients with CD. Anti-Saccharomyces cerevisiae antibody [ASCA] has been identified as the most accurate single marker in CD as yet. It is questionable whether other markers can identify a specific subset of CD patients. 2 Enhanced formation of autoantibodies against acinar cells of the exocrine pancreas in patients with CD and coeliac disease was reported. 3 Presence of pancreatic autoantibodies [PAbs] was identified first by indirect immunofluorescence technique [IIFT] , 4 and human and primate pancreas substrate has been used as the primary diagnostic test for PAbs so far. PAbs are present in up to 40% of the patients with CD and can be used to differentiate CD from UC. 2 Furthermore some studies, including the one with the largest patient cohort, have suggested that presence of PAbs is associated with specific disease phenotypes and their detection may be of clinical significance. 5, 6 More recently, the target antigens of PAbs have been identified: the pancreatic major glycoprotein GP2 of the zymogen granule membrane and CUZD1 protein [CUB and zona pellucida-like domains 1]. 7, 8 In the study of Komorowski et al., the authors verified that the formerly reported reticulogranular pattern in tissue sections of human pancreas by IIFT is strictly correlated with the presence of anti-CUZD1, whereas droplet pattern is correlated with the presence of anti-GP2 antibodies. 9 Furthermore, investigation of GP2 and CUZD1 revealed that they belong to protein families involved in innate and adaptive immunity. 10, 11 Presumably GP2 and CUZD1 may be involved in maintaining the balance between tolerance to commensal bacteria and immune response against pathogens. 12 Identification of the autoantigens has facilitated the development of new diagnostic tools for evaluation of PAbs, such as enzymelinked immunosorbent assay [ELISA] with isoform 4 of recombinant GP2 13 or advanced CUZD1 and GP2 expressing cell-based IIFT.
14 Experience with these newly available techniques for PAb detection is scarce, especially on the clinical importance of PAbs in CD. Recombinant GP2-based ELISA systems were used primarily in these studies. In contrast, information about anti-CUZD1 is very limited. 9 Presence of anti-GP2 was associated with stricturing behaviour with perianal disease in some 15, 16, 17 but not all studies. 18 However, studies were limited by cross-sectional design. Longitudinal follow-up studies are needed to unravel the clinical importance of these antibodies in CD prognosis. For this, studies should also investigate long-term stability of PAbs
The primary aim of the present study was to determine the predictive potential of the different PAbs with regard to the development of disease-specific complications or need for surgery in a large prospective referral CD cohort. The secondary aims were to investigate: [1] the long-term stability of the PAbs response; [2] association of PAbs formation to the clinical, serological and genetic characteristics of CD; and lastly [3] to define the agreement between the new diagnostic tools for the evaluation of different target-specific PAbs. The clinical characteristics of the patients at diagnosis are presented in Table 1 . Diagnosis of IBD was based on the LennardJones criteria. 19 The disease phenotype [age at onset, duration, location, and behaviour] was determined according to the Montreal Classification. 20 Blood samples and detailed clinical phenotypes were captured at inclusion. Clinical data were determined by thorough review of patients' medical records, which had been collected in a uniform format. 25 and the endoscopic component of the Mayo score in UC. 26 SES-CD defines endoscopic activity ≥ 3 points and inactive disease ≤ 2 in CD, whereas in UC the state of active disease was defined as invasive partial Mayo score ≥ 1.
Material and Methods

Patient population
Phenotypical characterisation of CD patients during prospective follow-up
CD patients were enrolled into a prospective follow-up study, where the treating IBD physicians registered laboratory data, endoscopic and imaging findings, disease activity, medical treatment, date and type of complications, and surgery during regular and extraordinary outpatient follow-up visits and inpatient stays. In Hungary, a follow-up visit is usually scheduled for every 6 months at a specialised gastroenterology centre [the actual interval varies between 3 and 6 months]. The treatment algorithms, both the medical and the surgical, are harmonised and followed the actual ECCO guidelines. 24, 2728, 29, 30 Need for surgery and timing of the resection is a consistent multidisciplinary decision with the collaboration of the gastroenterologist, radiologist, and surgeon. Collected data were transferred and stored in a database for analysis. In October 1, 2013, all patients' charts and database were reviewed and updated for the data points mentioned above. Follow-up for a particular patient was terminated if there was no further record available. Median follow-up from diagnosis was 108 months [IQR, . In CD, complicated disease behaviour was defined as the occurrence of stenosis or internal penetration. Perianal fistulising disease was distinguished from internal penetrating disease and evaluated separately. Need for surgery was defined as CD-related abdominal surgery [resection] . Figure 1 summarises the flow chart of the patients with CD in the cohort study. The control group consisted of 100 age-and gender-matched healthy blood donors (male/female: 46/54, median age at presentation, 30 years [IQR, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] ). The control subjects did not have any gastrointestinal and/or liver disease and were selected from consecutive blood donors in Debrecen.
Serological analysis
Blood samples were obtained at enrolment from each patient and were frozen at -80°C until testing. All the serological assays were performed in a blinded fashion without prior knowledge of the patient's diagnosis or other clinical information.
Detection of antibodies to GP2 by enzymelinked immunosorbent assays
Glycoprotein 2 autoantibodies were detected in sera of patients and controls using two different ELISAs employing recombinant human GP2 isoform 4 as solid-phase antigen (anti-MZGP2 IgA and IgG QUANTA Lite® ELISA [Inova Diagnostics, San Diego, CA, Research Use Only] and anti-GP2 IgA and IgG ELISA [GA Generic Assays, Dahlewitz/Berlin, Germany]) according to the manufacturers' instructions. Briefly, 100 µl of pre-diluted sera [1:100] was added to separate wells of MZGP2 or GP2 antigen-coated polystyrene microwells and incubated for 30 min and 60 min, respectively, at room temperature. Unbounded sample was then washed away and peroxidase-conjugated goat anti-human IgA antibody or antihuman IgG antibody was added to each well and developed with ready-to-use hydrogen peroxide / tetramethylbenzidine chromogenic substrate. The reaction was terminated with sulphuric acid and optical density of the samples was read at wavelength of 450/620 nm. Results expressed in arbitrary units [AU/ml], were calculated with reference to a kit-provided calibrator. Serum samples showing ≥ 25 AU/ml for anti-MZGP2 and ≥ 20 AU/ml for anti-GP2, respectively, were interpreted as positive.
Detection of antibodies to GP2 and CUZD1 by indirect immunofluorescence tests
Anti-GP2 and anti-CUZD1 IgA and IgG were detected in sera of patients and controls using cell-based IIFT [Morbus-Crohn Mosaic 1, Euroimmun Medizinische Labordiagnostika AG, Lübeck, Germany]. Biochips coated with transfected HEK293 cells, expressing GP2 and CUZD1 separately, are applied as substrates and were co-incubated with pre-diluted sera [1:10, 1:100, and 1:1000] for 30 min at room temperature. Unbounded sample was then washed away and fluorescein-labelled goat anti-human IgA or IgG antibodies were used to visualise bound antibodies of the patients' sera. Evaluation was performed using a Eurostar 
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Statistical analysis
Results
Frequency of anti-pancreatic antibodies in IBD
The frequencies of the different antibodies in IBD and controls are summarised in Table 2 . Significantly more, 10.2%, 12.2%, 10.2%, and 20.8% of the CD patients were positive for anti-GP2 IgA/IgG, anti-MZGP2 IgA/IgG, anti-rPAg2 IgA/IgG, and also for anti-CUZD1 [≈ anti-rPAg1] IgA/IgG antibodies compared with both UC and healthy controls [p < 0.01 for all], respectively. In addition, significant differences were found for both IgA and IgG subtypes. In contrast, the positivity rate was not different in UC and controls.
Anti-GP2 and anti-MZGP2 antibody titres were higher in CD compared with UC. The difference of the median titres for all antibodies, except anti-MZGP2 IgA, between CD and UC was statistically significant [MannWhitney, anti-GP2 IgA p < 0.001, anti-GP2 IgG p < 0.001, anti-MZGP2 IgA p = 0.12, anti-MZGP2 IgG p < 0.001]. In the surgery-naïve patient group [n = 234], progression to first resective surgery was faster in patients positive for anti-GP2 IgA antibody [pLogRank = 0.002] [ Figure 2 ]. At the same time, in postoperative settings, the presence of anti-GP2 IgA antibody was not able to predict a subsequent resective surgery in patients with previous surgery [n = 109].
Correlation of anti
To further evaluate the predictive potential of the PAb markers, we used a Cox-proportional hazard regression model adjusted to gender and clinical variables with a p-value of < 0.1 in univariate time-dependent models [Kaplan-Meier and LogRank analysis]. Anti-CUZD1 IgA and anti-GP2 IgA were analysed separately. Table 2 . Serological markers in patients with Crohn's disease, ulcerative colitis, and healthy controls.
CD UC HCONT
Anti-GP2 n = 266 Anti-GP2 n = 183 Anti-GP2 n = 100
Anti-MZGP2 n = 266 Anti-MZGP2 n = 185 Anti-MZGP2 n = 100
Anti-rPAg n = 264 Anti-rPAg n = 178 Anti-rPAg n = 100 Anti-CUZD1 IgA was identified as an independent predictor for the development of perianal disease both in the primary model [ Table 4 ] and in the model in the same sensitivity analysis [data not shown].
In contrast, the association between anti-GP2 and need for resective surgery was lost in the multivariate model [ 
Interassay study for anti-GP2 antibodies
Altogether, the agreement among the three different assays ranged from 94.0% to 95.6% for anti-GP2 IgG and from 91.6% to 96.4% for anti-GP2 IgA. 
Discussion
In the present study, we investigated the clinical importance of different target-specific PAbs in the prediction of complicated disease behaviour and surgery in adult CD patients. To our knowledge, this is the first prospective study on the new PAbs. In addition, we proved the long-term stability of PAb status over time and confirmed good agreement among newly available diagnostic tools for evaluation of anti-GP2 antibodies. Significantly more CD patients were positive for different PAbs compared with both UC patients and healthy controls. The formation of autoantibodies against GP2 and CUZD1 glycoproteins may reflect an immune response against an overwhelming microbial challenge to the intestinal barrier. Anti-GP2 antibody titres were higher in CD compared with UC as well. The magnitude of antibody responses [titres] may correlate with the extent of bacterial translocation [BT], which is more pronounced in CD compared with UC. One possible explanation is that in UC the inflammation is confined to the mucosa whereas in CD it is transmural. Another explanation might be that the disturbance of mucosal immunity is different between the two diseases. It is further supported by the findings that the presence of GP2 was confirmed at the intestinal site of inflammation in patients with CD. 32 In previous clinical studies, presence of anti-GP2 antibodies was associated with distinct clinical phenotype of CD such as early disease onset, ileal involvement, and stricturing disease behavior, but results differed among studies. However, in the single study identifying anti-CUZD1 antibody as a distinct PAb type, the association with clinical phenotype or disease course was not assessed in CD. 9 Interestingly, clinical associations were different for anti-GP2 and anti-CUZD1 antibodies in the present cohort, which may be at least partly the consequence of differences in the target proteins of these antibodies belonging to distinct innate immunity protein families. Prevalence of anti-GP2 antibodies was higher in our patients with paediatric onset, in concordance with findings of some previous studies. 14, 15 Regarding disease location, we were also able to confirm that presence of anti-GP2 antibodies was associated with extensive disease with ileal involvement. 14, 15, 16 Of note, some reports failed to identify an association between anti-GP2 antibodies and disease location 33 or this was limited to only upper gastrointestinal tract involvement. Rows corresponding to location and perianal disease at diagnosis, NOD2/CARD15 mutations, and need for systemic GCS at last follow-up were omitted because statistically significant differences for a given parameter
were not obtained; positive associations are indicated in bold and negative associations in italic [p-values, odds ratio, and 95% confidence intervals]. PAbs, pancreatic autoantibodies; GCS, systemic glucocorticoids; PSC, primary sclerosing cholangitis.
Anti-CUZD1 antibodies were more frequent in patients with colonic involvement. Penetrating disease was associated with anti-GP2 positivity in the present CD cohort. In the study of Bogdanos et al., 15 anti-GP2 IgG were significantly more prevalent in patients with stricturing behaviour and perianal disease, but less prevalent in those with penetrating behaviour, whereas other studies did not find significant association between anti-GP2 antibodies and complicated disease behaviour. 14, 18 Thus far, no study has evaluated associations between target-specific PAbs and extraintestinal manifestations. We found that PSC was associated with the presence of anti-GP2, whereas cutaneous manifestations were associated with anti-CUZD1 antibodies. Of note, despite these differences between the clinical phenotypes, the concordance among the three assays was good. Each test recognised also an additional patient population that was missed by the other[s], suggesting partly non-overlapping epitopes.
Our findings support that PAbs may contribute to better stratification of CD patients. Prevalence is relatively low, and so the clinical utility of PAbs in the diagnosis and prediction of disease course in CD may be more modest compared with ASCA which remains the most accurate single marker in CD so far. 2 However, anti-GP2 antibody has been shown to be more specific for CD than ASCA recently, and the specificity of double-positive patients with CD is 100%.
14 Of note, the prevalence rate of anti-GP2 IgA/IgG in our CD patients was even lower than rates reported previously [10.2-12 .4% vs 21.0-45.0%]. 34 Variation in the prevalence of serological markers among studies and in different ethnic populations is however well documented. 2 Moreover, methodological differences can also contribute to these differences. It is interesting to note that different isoforms of GP2 are synthesised in the pancreas. 35 A larger and a shorter isoform of GP2 were identified and termed alpha [GP2a] and beta [GP2b], respectively. 36 Previous prevalence data of anti-GP2 IgA and IgG, except one, 14 were obtained mainly by assays manufactured by GA Generic Assays employing the larger isoform for GP2-specific autoantibody detection initially. 13 In contrast, both ELISAs used in our study employed recombinant human GP2 isoform 4 as solidphase antigen corresponding to the shorter isoform [GP2b], because of better discrimination of patients with CD from those with UC. 35 For the long-term predictive potential of serological markers, it is necessary to assess the stability of antibody status over time. In terms of anti-GP2 antibody stability, only limited and conflicting data are available. 17 In the present study, long-term stability of different PAbs was assessed extensively. PAb status was not associated with actual disease activity, and positivity rates were stable over time in IBD patients. This is in contrast to anti-GP2 antibody levels detected in patients with coeliac disease where they were significantly reduced under a gluten-free diet. 3 Until now, only cross-sectional associative analyses have been available in CD patients. In addition, the present study provides longitudinal prospective results on the predictive potential of PAbs for identifying disease-specific complications and surgery requirements. PAb positivity was able to predict faster progression to complicated disease in our patient cohort. Anti-GP2 positivity was associated with the need for surgical interventions, and anti-CUZD1 predicted development of perianal complications. Regarding anti-GP2, previously only two cross-sectional studies evaluated surgical outcome, with conflicting results. 16, 18 Of note however, treatment strategy may vary among countries, IBD centres and even doctors, which is a clear confounder of all studies. Therefore association between serology and surgical findings in the present study should be interpreted with caution. However, one of the main strengths of our study is the analysis of outcomes during a prospective follow-up period. The frequency of regular follow-up was 3-6 months in the majority of the patients. Silverberg et al. 20 suggested that long-term complications and outcomes should be studied during an approximate 5-year follow-up. Of note, 79.2% of the CD patients in the present cohort had at least a 5years of follow-up. In addition, the collection of extensive disease phenotypes enabled adjustment for possible confounders. In the final Cox-regression multivariate model, anti-CUZD1 antibody positivity was a strong independent predictor for the development of perianal complications, including age at diagnosis, sex, disease location and behaviour, and relapse frequency as potential confounders. Our results await replication in independent patient cohorts both from referral centres and from population-based cohorts.
Interestingly, in our study IgA but not IgG PAbs types were associated with complicated disease course in CD. The gut mucosal immune system plays a central role in the IgA antibody formation, and this may at least partly reflect an immune response against an overwhelming microbial challenge. In addition, IgA type autoantibodies are considered a sign of immunological response to enteric antigens in other diseases associated with enhanced bacterial translocation. Moreover, IgA type antibodies were reported to have a pivotal role in the development of disease-specific complications compared with the IgG antibody subtype. 37 Our clinical findings are concordance with a previous hypothesis from Roggenbuck et al. 12, 17 According to this hypothesis, plasma cells can synthesise anti-GP2
IgA after the loss of tolerance towards GP2, which will be actively transported by the epithelium into the intestinal lumen. Indeed, anti-GP2 IgA has been found in faeces of patients with pouchitis exhibiting CD-like complications. 38 The secreted anti-GP2 IgA can bridge FimH-positive bacteria opsonised by pancreatic GP2 with the membrane-bound GP2 on the M cells. Ultimately, this may lead to a mucosal overload of microbes in CD due to elevated transcytosis accelerating intestinal inflammation.
In conclusion, the findings of our prospective referral cohort study indicate that target-specific PAbs may be useful markers in the stratification of CD patients and are associated with complicated disease phenotype and risk of developing perianal complications. In addition, they may be valuable additional tools as a member of serology panels for the prediction of disease course.
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